FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256221230> ?p ?o ?g. }

• W4256221230 abstract "Abstract Background: [ 68 Ga]Ga-NeoB is a novel DOTA-coupled Gastrin Releasing Peptide Receptor (GRPR) antagonist with high affinity for GRPR and good in vivo stability. This study aimed at (1) the translation of preclinical results to the clinics and establish the preparation of [ 68 Ga]Ga-NeoB using a GMP conform kit approach and a licensed 68 Ge/ 68 Ga generator and (2) to explore the application of [ 68 Ga]Ga-NeoB in patients with gastrointestinal stromal tumors (GIST) before and/or after interventional treatment (selective internal radiotherapy, irreversible electroporation, microwave ablation). Results: Validation of the production and quality control of [ 68 Ga]Ga-NeoB for patient use had to be performed before starting the GMP production. Six independent batches of [ 68 Ga]Ga-NeoB were produced, all met the quality and sterility criteria and yielded 712 ± 73 MBq of the radiotracer in a radiochemical yield of >50%, a radiochemical purity of >95% and a molar activity of 14.2 ± 1.5 GBq/µmol within 20 min synthesis time and additional 20 min quality control. Three patients (2 females, 1 male, 51–77 yrs of age) with progressive gastrointestinal stromal tumor metastases in the liver or peritoneum not responsive to standard tyrosine kinase inhibitor therapy underwent both [ 68 Ga]Ga-NeoB scans prior and after interventional therapy. Radiosynthesis of 68 Ga-NeoB was performed using a kit approach under GMP conditions. No specific patient preparation such as fasting or hydration was required for [ 68 Ga]Ga-NeoB PET/CT imaging. Contrast-enhanced PET/CT studies were performed. A delayed, second abdominal image was acquired at 120 minutes p.i. of admistration of the first dose of [ 68 Ga]Ga-NeoB. Conclusions: A fully GMP compliant kit preparation of [ 68 Ga]Ga-NeoB enabling the routine production of the tracer under GMP conditions was established for clinical routine PET/CT imaging of patients with metastatic GIST and proved to adequately visualize tumor deposits in the abdomen expressing GRPR. Patients could benefit from additional information derived by [ 68 Ga]Ga-NeoB diagnosis to assess the presence of GRPR in the tumor tissue and monitor antitumor treatment." @default.
• W4256221230 created "2022-05-12" @default.
• W4256221230 creator A5004563938 @default.
• W4256221230 creator A5044741435 @default.
• W4256221230 creator A5046601855 @default.
• W4256221230 creator A5048547916 @default.
• W4256221230 creator A5052806645 @default.
• W4256221230 creator A5068640554 @default.
• W4256221230 creator A5081680068 @default.
• W4256221230 date "2021-05-06" @default.
• W4256221230 modified "2023-09-26" @default.
• W4256221230 title "­­­­GMP-conform production of [ 68Ga ]Ga-NeoB for positron emission tomography imaging of patients with gastrointestinal stromal tumor" @default.
• W4256221230 doi "https://doi.org/10.21203/rs.3.rs-446161/v1" @default.
• W4256221230 hasPublicationYear "2021" @default.
• W4256221230 type Work @default.
• W4256221230 citedByCount "0" @default.
• W4256221230 crossrefType "posted-content" @default.
• W4256221230 hasAuthorship W4256221230A5004563938 @default.
• W4256221230 hasAuthorship W4256221230A5044741435 @default.
• W4256221230 hasAuthorship W4256221230A5046601855 @default.
• W4256221230 hasAuthorship W4256221230A5048547916 @default.
• W4256221230 hasAuthorship W4256221230A5052806645 @default.
• W4256221230 hasAuthorship W4256221230A5068640554 @default.
• W4256221230 hasAuthorship W4256221230A5081680068 @default.
• W4256221230 hasBestOaLocation W42562212301 @default.
• W4256221230 hasConcept C126322002 @default.
• W4256221230 hasConcept C150903083 @default.
• W4256221230 hasConcept C16930146 @default.
• W4256221230 hasConcept C207001950 @default.
• W4256221230 hasConcept C2775842073 @default.
• W4256221230 hasConcept C2775922572 @default.
• W4256221230 hasConcept C2776970183 @default.
• W4256221230 hasConcept C2777007597 @default.
• W4256221230 hasConcept C2989005 @default.
• W4256221230 hasConcept C3017724952 @default.
• W4256221230 hasConcept C71924100 @default.
• W4256221230 hasConcept C86803240 @default.
• W4256221230 hasConceptScore W4256221230C126322002 @default.
• W4256221230 hasConceptScore W4256221230C150903083 @default.
• W4256221230 hasConceptScore W4256221230C16930146 @default.
• W4256221230 hasConceptScore W4256221230C207001950 @default.
• W4256221230 hasConceptScore W4256221230C2775842073 @default.
• W4256221230 hasConceptScore W4256221230C2775922572 @default.
• W4256221230 hasConceptScore W4256221230C2776970183 @default.
• W4256221230 hasConceptScore W4256221230C2777007597 @default.
• W4256221230 hasConceptScore W4256221230C2989005 @default.
• W4256221230 hasConceptScore W4256221230C3017724952 @default.
• W4256221230 hasConceptScore W4256221230C71924100 @default.
• W4256221230 hasConceptScore W4256221230C86803240 @default.
• W4256221230 hasLocation W42562212301 @default.
• W4256221230 hasLocation W42562212302 @default.
• W4256221230 hasOpenAccess W4256221230 @default.
• W4256221230 hasPrimaryLocation W42562212301 @default.
• W4256221230 hasRelatedWork W2076878947 @default.
• W4256221230 hasRelatedWork W2268272285 @default.
• W4256221230 hasRelatedWork W2324255118 @default.
• W4256221230 hasRelatedWork W2389171195 @default.
• W4256221230 hasRelatedWork W2419232549 @default.
• W4256221230 hasRelatedWork W2980728424 @default.
• W4256221230 hasRelatedWork W3134813758 @default.
• W4256221230 hasRelatedWork W3159252641 @default.
• W4256221230 hasRelatedWork W4256221230 @default.
• W4256221230 hasRelatedWork W1909518227 @default.
• W4256221230 isParatext "false" @default.
• W4256221230 isRetracted "false" @default.
• W4256221230 workType "article" @default.